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Abstract
Background: High risk human papillomaviruses (HR-HPV) are known to be extremely common, sexually transmitted
infections, but more information is needed regarding the absolute risks of type-specific HR-HPV infections in the
years following sexual debut.
Methods: We conducted a survival analysis of 3,737 women aged 18–25 from the control group of the Costa Rican
Vaccine trial to determine the absolute risks of HR-HPV infections at 12 months, 24 months, and end of follow-up
(average of 50.7 months). To corroborate determinants of infection, we used Cox proportional hazards methods to
assess associations between demographics and sexual risk behaviors and incident HR-HPV.
Results: Cumulative incidence for HR-HPV infections was 51.3% at the end of the study period. The most
common incident types were HPV52 (15.4%), HPV51 (13.6%), and HPV16 (12.4%). Type-specific cumulative
incidence corresponded closely with type-specific prevalences, except that HPV16 was more prevalent than
predicted by incidence, suggesting greater persistence. The strongest predictors of incident HR-HPV infections as
a group in a multivariate analysis were the expected correlates of sexual behavior of the woman and her partner,
such as being single (HR 1.6, 95% CI 1.4-1.8) or divorced/widowed (HR: 2.1, 95% CI: 1.7-2.7), having multiple HPV
infections at enrollment (HR: 1.5, 95% CI: 1.3-1.7), and current smoking (HR: 1.2, 95% CI: 1.0-1.3). In women who
reported being having only one lifetime sexual partner (being in a monogamous relationship), the strongest
predictors of HR-HPV included not living with sex partner (HR: 2.1, 95% CI 1.7-2.5) and age of sex partner (HR: 1.4,
95% CI: 1.0-1.8).
Conclusion: We confirm the extremely high incidence of HR-HPV in young women, emphasizing the importance
of vaccinating young girls before sexual debut.
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Background
Human papillomavirus (HPV) infections are easily trans-
mitted by sexual contact and are very common among
sexually active young women [1,2]. Approximately 90%
of all HPV infections will clear (or become undetectable
using standard methods) within a few years, yet a small
proportion of persistent, carcinogenic HPV infections (HR-
HPV) will eventually cause cervical cancer if precancerous
lesions are not treated [3]. Currently, a prophylactic vac-
cine is available for HR-HPV types 16 and 18. The vaccine
efficacy is high for types 16 and 18, and has also been
shown to provide partial protection for types 31, 33, and
45 [4], yet other HR-HPV types are not known to be at all
protected against by the vaccine. The absolute risks of
acquiring individual cervical HR-HPV infection are not
adequately defined; such analyses are surprisingly uncom-
mon in the literature because they require large-scale HPV
typing of sizable longitudinal studies.
The determinants of HPV infection acquisition, all types
combined, are better defined. Risk for HPV acquisition is
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strongly associated with sexual behavior [1,3,5]. There
is evidence to support that use of condoms and circum-
cision of the male partner reduces rates of HPV trans-
mission [6,7].
Characterizing more fully the incidence of new HR-HPV
infections in young sexually active women would be
informative for models of HR-HPV transmission and
vaccination impact. The Costa Rican Vaccine Trial (CVT)
control arm provides an opportunity to study a large
number of recently acquired HR-HPV infections within
a group of young women aged 18–25 years old. Such a
young and narrow age range enables us to look at the
acquisition of new HR-HPV infections, presumably around
the onset of sexual activity. The primary purpose of this
study was to define the absolute risk of HR-HPV and type-
specific HR-HPV infection in our cohort of young women.
Secondarily, we wished to add to the already substantial
literature on determinants of transmission. We were
also interested in confirming or refuting our prior belief




The study population consisted of all 3,739 women par-
ticipating in the control group of the Costa Rican Vaccine
Trial (CVT; NCT00128661)). Study design and proce-
dures have been described elsewhere [8]. Briefly, CVT is a
community-based, double-blind randomized phase III trial
aimed at evaluating the efficacy of HPV 16/18 bivalent
vaccine in preventing cervical precancers. At enroll-
ment, women provided written informed consent. The
trial recruited 7,466 women aged 18–25 years from the
Guanacaste and Puntarenas provinces, Costa Rica. The
vaccination schedule for both groups was three doses:
one at enrollment, one month, and six months later.
After receiving the vaccines, women were followed once
per year for at least four years if their cytology was nor-
mal, and were transferred to a six-month follow-up
schedule if they had HPV-related cytological abnormal-
ities. We excluded women in the vaccine arm because
we wanted to measure the true incidence and determinants
of HR-HPV acquisition in an unvaccinated population.
All participants were administered an enrollment ques-
tionnaire by a trained interviewer. The questionnaire elic-
ited information on level of education, marital status,
household facilities, menstrual history, sexual, reproduct-
ive, and contraceptive history, smoking, and family history
of cancer. Among women who reported being in a mon-
ogamous relationship, additional questions were asked
about their sexual partner including their age, educa-
tion, circumcision status, sexual history, and smoking
history. All study protocols were reviewed and approved
by the National Cancer Institute and Costa Rican Insti-
tutional Review Boards.
HPV DNA testing
Exfoliated cervical cells were collected using a Cervex
brush and rinsed into a vial of 20 mL of PreservCyt so-
lution during the pelvic exam. Samples were tested for
HPV DNA by polymerase chain reaction (PCR) amplifi-
cation with SPF10 primers followed by DNA enzyme im-
munoassay detection of amplimers. HPV typing on positive
amplimers was performed using line probe assay (LiPA25).
All HPV positive samples that were HPV16/18 negative by
LiPA25 were tested by type-specific PCR. Carcinogenic HPV
types, termed high-risk HPV (HR-HPV) in this analysis, in-
cluded 16,18,31,33,35,39,45,51,52,56,58, and 59 . Other HPV
types, characterized as low-risk HPV (LR-HPV) included 6,
11, 34, 40, 42, 43, 44, 53, 54, 66, 68, 70, 73, 74, and unknown
types. The typing assay does not distinguish HPV68 and
HPV73: they were included conservatively as low-risk.
Statistical analysis
For each individual HPV type, we estimated the 12 and
24 month and overall cumulative incidence. Incidence
implied new detection of that HPV type for women who
were or became sexually active who were completely
HPV negative at enrollment or who were positive only
for other types. Months at risk were calculated on the
basis of number of months from the enrollment visit to
detection of an incident HPV type or at the last follow-
up visit, if a woman remained negative for that type
throughout the study. Event times were calculated as
the midpoint of the intervals between the last HPV type
negative and the first HPV type positive visit.
Socio-demographic, sexual behavior, contraceptives,
smoking and reproductive history characteristics mea-
sured at enrollment, as well as prevalent HPV infection
and number of prevalent HPV types were evaluated as
possible determinants of incident HR-HPV and LR-HPV
infection. Continuous questionnaire variables were cat-
egorized based on trends in the data when appropriate.
The five questions regarding household facilities were
characterized as an overall measure of socioeconomic
status (SES). Women who had all five household amen-
ities (electricity, refrigerator, toilet, television, and run-
ning water) were considered to have high SES while
women who had less than all five were categorized as
low SES. The variable, years of sexual activity was
calculated by subtracting the women’s age at sexual
debut from her age at enrollment. Questionnaire vari-
ables that only pertained to women having only one
lifetime sexual partner were evaluated separately. From
now on these women will be referred as being in
“monogamous” relationships.
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Cox proportional hazards regression models were used
to evaluate the relationship between enrollment ques-
tionnaire variables and time to incident HPV infection.
Variables that were significant at the p ≤ 0.10 level or
below in the univariate analysis as well as those that were
of particular interest for this study, (i.e. circumcision
status and condom use) were considered in multivariate
regression models. The final models included variables
that were significant at the p ≤ 0.05 threshold and col-
linearity between covariates was assessed by calculating
variance inflation factors for each variable after fitting
the mulitvariable regression models. Two women were
excluded for having a questionnaire that was deemed
unreliable by the interviewer, leaving a total of 3,737
women in the final analysis. All analyses were conducted
using STATA (version 11.0; StataCorp).
Results
Prevalent and incident HR-HPV infections
On average, women attended 4.476 screening follow-up
visits throughout the study. Total person-months at risk
was estimated to be 114,062.8 months for all HR-HPV
types (data not shown). Table 1 shows the type-specific
prevalence and cumulative incidence of HR-HPV, LR-HPV,
and type-specific HR-HPV by time intervals, ending at
the end of follow-up (averaging about 50 months for
most women). HPV typing data was available for 3,731
women. At enrollment, 947 (25.3%) women were HR-HPV
positive and 812 (21.8%) were LR-HPV positive. HPV16
was the most common prevalent type (7.1%), followed by
HPV52 and HPV51, respectively. Cumulative incidence
was slightly higher for LR-HPV types compared to HR-
HPV types (54.3% vs. 51.3%, respectively). Type-specific
HR-HPV cumulative incidence varied, with HPV52 being
the most common (15.4%, 95% CI: 14.3-16.7%), followed
by HPV51 (13.6%, 12.5-14.7%) and HPV16 (12.4%, 11.4-
13.5%). Figure 1 shows a plot of type-specific HR-HPV
prevalence versus cumulative incidence. A correlation was
observed between the most common prevalent and inci-
dent types, with the exception of HPV16, which was highly
prevalent compared to all other HR-HPV types, but had
the third highest cumulative incidence. The cumulative
incidence of multiple HR-HPV types was 32.9% (31.3-
34.7%) and a total of 1,022 women remained HPV nega-
tive throughout the entire study (data not shown).










% Cumulative HPV incidence
end of follow-up^
HR-HPV 25.3 74.7 29.4 43.0 51.3
LR-HPV 21.8 78.2 31.7 47.4 54.3
HPV16 7.1 92.9 5.7 9.8 12.4
HPV18 2.5 97.5 3.5 6.3 8.2
HPV31 3.8 96.2 4.7 8.0 10.5
HPV33 1.0 99.0 1.7 3.1 3.8
HPV35 1.3 98.7 2.4 3.6 4.8
HPV39 3.2 96.8 3.7 6.1 8.3
HPV45 1.7 98.3 3.0 5.3 6.5
HPV51 4.2 95.8 6.1 10.8 13.6
HPV52 5.1 94.9 6.3 12.1 15.4
HPV56 3.2 96.8 4.0 7.5 9.8
HPV58 2.4 97.6 3.6 6.0 7.8
HPV59 1.3 98.7 2.4 4.9 6.3
# Incidence defined by new detection of HPV type for women who were completely HPV negative at enrollment or who were positive only for other types.
^Average end of follow-up is 50.7 months, very few women had a maximum end of follow-up of 76 months.
HR, High Risk; LR, Low Risk.
Figure 1 A plot of the percent prevalence versus percent
cumulative incidence by HR-HPV type.
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Univariate associations for risk of incident HR-HPV
Table 2 presents the univariate associations for HR-HPV
incidence among the 3,737 women included in this study.
Within the restricted age range, age at enrollment was
not related to HR-HPV acquisition. HR-HPV acquisition
was significantly associated with being single or divorced/
widowed, high SES, not being a virgin at enrollment, not
being in a monogamous relationship, fewer years since
initiation of sexual activity, greater number of sex part-
ners, and a history of cigarette smoking within the past six
months. Lifetime OC use and lifetime injectable contracep-
tive use were protective against incident HR-HPV while
history of condom use and use of barrier methods (both
condoms and diaphragms) significantly increased the risk
of HR-HPV acquisition. Being positive for any HPV type at
enrollment significantly increased the risk of incident HR-
Table 2 Univariate cox proportional hazards regression analysis for incident HR-HPV among Women in the Costa Rican
Vaccine Trial
Woman characteristics Total Positive for one or more new HR-HPV types
n Col % n % HR (95% CI)
Age at Enrollment (years) 18-20 1,729 46.4 864 50.0 1.1 (1.0 – 1.2)
21-25 2,002 53.6 947 47.3 Ref
Marital Status Divorced/Widowed 98 2.6 70 71.4 2.5 (1.9 – 3.1)
Single 2,082 56.0 1,084 52.1 1.4 (1.3 – 1.5)
Married or living as 1,544 41.4 654 42.4 Ref
Measures of SES All 5 3,012 80.7 1,517 50.4 1.3 (1.2 – 1.5)
<5 719 19.3 294 40.9 Ref
Virgin at Enrollment No 2,918 78.2 1,543 52.9 2.0 (1.7 – 2.2)
Yes 813 21.8 268 33.0 Ref
Years Sexually Active <1-2 674 23.1 393 58.3 1.4 (1.2 – 1.7)
3-4 812 27.9 430 53.0 1.2 (1.1 – 1.5)
5-7 890 30.6 461 51.8 1.1 (1.0 – 1.3)
>7 536 18.4 256 47.8 Ref
Monogamous Relationship No 2,489 66.7 1,253 50.3 1.2 (1.1 -1.4)
Yes 1,242 33.3 558 44.9 Ref
Number of Sex Partners 3+ 902 31.2 560 62.1 1.7 (1.5 – 1.9)
2 749 25.9 408 54.5 1.4 (1.2 – 1.6)
1 1,242 42.9 558 44.9 Ref
Duration Sexual Relationship with Partner (days) 1-330 1,051 36.3 608 57.9 1.5 (1.3 – 1.7)
331-1200 1,022 35.3 546 53.4 1.3 (1.2 – 1.5)
1201-4380 824 28.4 376 45.6 Ref
Lifetime Oral Contraceptive Use No 562 20.0 360 64.1 1.5 (1.3 – 1.7)
Yes 2,255 80.0 1,124 49.8 Ref
Lifetime Injectable Contraceptive Use No 1,685 59.8 911 54.1 1.2 (1.0 – 1.3)
Yes 1,133 40.2 571 50.4 Ref
Lifetime Condom Use Yes 1,729 61.3 933 54.0 1.2 (1.1 – 1.3)
No 1,092 38.7 550 50.4 Ref
Use of Barrier Methods During Sex Condom/Diaphragm 788 27.1 465 59.0 1.3 (1.2 – 1.4)
Neither 2,123 72.9 1,074 50.6 Ref
Smoked Cigarettes in Past 6 Months Yes 499 13.4 317 63.5 1.7 (1.5 – 1.9)
No 3,225 86.6 1,491 46.2 Ref
HPV Positive at Enrollment Yes 1,459 39.1 902 61.8 2.0 (1.8 – 2.2)
No 2,272 60.9 909 40.0 Ref
Number of Enrollment HPV Infections 2 or more types 549 14.7 361 65.8 2.3 (2.0 – 2.6)
1 type 910 24.4 541 59.5 1.9 (1.7 – 2.1)
0 types 2,272 60.9 909 40.0 Ref
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HPV infection, as did being infected with more than one
HPV type. We assessed whether history of condom use
was confounded by increased frequency of sexual activity
and found that risk of HR-HPV was no longer associated
with condom use when adjusting for number of sexual
partners. To determine whether being single or divorced
was a proxy for more sexual relationships, we stratified the
analysis of marital status by whether a woman was in a
monogamous relationship. However, the hazard ratios (HR)
were similar for women who were not in a monogamous
relationship (single: HR: 1.1, 95% CI: 1.0-1.3 and divorced:
HR: 2.0, 95% CI: 1.5-2.6) and women who were in a mon-
ogamous relationship (single: HR: 1.9, 95% CI: 1.6-2.1 and
divorced: HR 2.0, 95% CI: 1.5-2.7). We observed very similar
univariate associations for LR-HPV types (data not shown).
Among women who were in monogamous relation-
ships (Table 3), younger age of sex partner, sex partner
having had sexual intercourse with more than one other
woman in their lifetime, not living with sex partner, and
sex partner having a lifetime history of smoking were
significantly associated with increased risk of incident
HR-HPV infection. Male partner’s circumcision status
(reported by female partner) was not correlated with a
decreased risk of HR-HPV acquisition, although the re-
sponse rate for this question was very low (about 1/3 of
participants). Similar associations were observed for
LR-HPV types (data not shown).
Multivariate analysis for risk of incident HR-HPV
In the multivariate model shown in Table 4, after con-
trolling for age at enrollment, significant associations for
acquisition of a new HR-HPV type included being single
or divorced/widowed, high SES, shortest time since initi-
ation of sexual activity (<1-2 years), not being in a mon-
ogamous relationship, never using birth control pills,
history of cigarette smoking within the past six months,
and being positive for one or more HPV infections at
enrollment. For LR-HPV types, only marital status and
number of enrollment HPV infections were significant
in the multivariate model (data not shown). Among
women in monogamous relationships, not living with your
sex partner, young age of sex partner, partner’s lifetime
history of smoking, and sex partner having intercourse
with two or more other women were significantly associ-
ated with increased risk of incident HR-HPV. Similar as-
sociations were observed for LR-HPV types, with the
exception of age of sex partner which was not included
in the model (data not shown).
Risks for the three most prevalent and incident HR-HPV
types: 16, 51, and 52
To determine if infection with the three most prevalent
HR-HPV types influenced the subsequent incidence of
other HR-HPV types, we conducted a Cox proportional
hazard analysis in which prevalent infection with HPV16,
HPV52, or HPV51 was used as a predictor of incident in-
fection with other HR-HPV types. As predicted, we found
that risk of incident HR-HPV infection of any type signifi-
cantly increased if a woman was positive for HPV16,
HPV52, or HPV51 at enrollment (data not shown).
In the univariate analysis of risk factors for HR-HPV
incidence, we observed similar associations for HPV16,
HPV51, and HPV52 to all HR-HPV types.
Discussion
Our study confirms the high incidence of HR-HPV among
sexually active young women. HPV16 was the most com-
mon prevalent type at study enrollment and HPV52 was
the most frequently detected incident type, followed by
HPV51 and HPV16. A graphical representation of prevalent
Table 3 Univariate cox proportional hazards regression analysis for incident HR-HPV among women in monogamous
relationships in the Costa Rican Vaccine Trial
Total Positive for one or more new HR-HPV types
Woman characteristics N Col (%) N % HR (95% CI)
Age of Sex Partner (years) 16-24 542 43.8 268 49.5 1.4 (1.1 – 1.8)
25-30 483 39.1 207 42.9 1.1 (0.9 – 1.5)
>30 212 17.1 80 37.7 Ref
Number of Other Women Sex Partner has had Sex with 2+ 467 47.6 228 48.8 1.2 (1.0 – 1.6)
1 271 27.6 109 40.2 1.0 (0.7 – 1.3)
0 243 24.8 104 42.8 Ref
Lives with Sex Partner No 458 36.9 270 59.0 2.1 (1.8 – 2.5)
Yes 784 63.1 288 36.7 Ref
Partner is Circumcised Yes 604 52.9 267 44.2 1.0 (0.9 – 1.2)
No 538 47.1 241 44.8 Ref
Sex Partner Ever Smoke Yes 355 28.6 188 53.0 1.3 (1.1 – 1.6)
No 886 71.4 370 41.8 Ref
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and incident HPV types confirms a correlation between
frequency of prevalent types and incident types, with the
exception of HPV16. The high prevalence of HPV16 rela-
tive to its incidence might suggest longer persistence. As
expected, risk of incident HR-HPV infection was strongly
influenced by variables related to sexual behavior. Both
HR-HPV and LR-HPV had similar risk predictors for inci-
dent infection.
The high incidence rates we observed in our study are
expected from a population of young sexually active women
and are similar to other prospective studies of HPV inci-
dence among young women in the United States, Denmark,
Colombia, Brazil, and Canada [3,9-12]. Many of the risk
factors for incident HR-HPV observed in this study have
been reported elsewhere and confirm that risk of incident
HR-HPV infection is strongly influenced by sexual behav-
ior [1,3,9,13]. High SES was associated with increased risk
of HR-HPV. Some population-based surveys have reported
that higher SES might sometimes be associated with a
greater number of sexual partners, at least among males
[14], though there are no data in the literature to suggest
that high SES increases risk for HPV infection apart from
a correlation with sexual behavior. The association be-
tween recent smoking history and partner's smoking
history is also not well understood. In addition to our
current findings, other studies that have shown a posi-
tive relationship between risk of HPV infection and
smoking, suggesting it may be a proxy for high risk sex-
ual behavior [10,15,16]. There is some, albeit inconsist-
ent, evidence suggesting that smoking may influence
Table 4 Multivariate cox proportional hazards regression analysis for risk of incident HR-HPV among all women and
women in monogamous relationships in the Costa Rican Vaccine Trial
All women
Women characteristics HR (95% CI)
Marital Status Married Ref
Single 1.7 (1.4 – 1.8)
Divorced/Widowed 2.1 (1.7 – 2.7)
Measures of SES Less than 5 Ref
All 5 1.2 (1.0 – 1.4)
Years Sexually Active 0-2 1.3 (1.1 – 1.6)
3-4 1.2 (1.0 – 1.4)
5-7 1.1 (1.0 – 1.3)
>7 Ref
Monogamous Relationship Yes Ref
No 1.4 (1.2 – 1.6)
Lifetime Oral Contraceptive Use Yes Ref
No 1.2 (1.0 – 1.3)
Smoked Cigarettes Past 6 Months No Ref
Yes 1.2 (1.0 – 1.4)
Number of Enrollment HPV Types 0 Ref
1 1.4 (1.3 – 1.6)
2+ 1.5 (1.3 – 1.7)
Women in Monogamous Relationships Only
Lives with Sex Partner Yes Ref
No 2.1 (1.7 – 2.5)
Age of Sex Partner (years) 16-24 1.4 (1.0 – 1.9)
25-30 1.4 (1.0 – 1.8)
>30 Ref
Sex Partner Ever Smoke No Ref
Yes 1.3 (1.1 – 1.6)
Number of Other Women Sex Partner has had Sex with 0 Ref
1 1.0 (0.8 – 1.3)
2+ 1.3 (1.0 – 1.6)
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the immune system [17]. Studies assessing the risk of
incident HPV infection and OC use have also been in-
consistent. Our findings indicate that lifetime OC use
has a protective effect against HR-HPV acquisition and
is in line with similar studies [13,18], yet others report
no association between OC use and incident HPV in-
fection or even increased risk [19-22].
We did not find evidence suggesting that condom use
was protective against HR-HPV acquisition, if anything
our data shows an increased risk of HR-HPV infection
with condom use, although this association was rendered
insignificant when controlled for other measures of sexual
behavior. There is conflicting data in the literature, several
cross-sectional studies have shown that condom use by
male partners does not reduce the risk of HPV infection
in women [10], yet others suggest that consistent use of
male condoms do effectively reduce the risk of HPV trans-
mission [6]. Since in our study, condom use was a proxy
for sexual activity, the modest association between in-
creased HR-HPV and reported condom use might be
explained by the fact that condoms are often not worn
during every sexual act and even when worn, there could
still be transmission.
We found no association between circumcision of male
partners and reduced HR-HPV risk among women in
monogamous relationships. The lack of association in our
study could be due to reliance on the woman’s report of
her male partner’s circumcision status, which may be
unreliable. Furthermore, only one-third of the women
included in this study responded to this this question,
therefore the estimation of male partner’s circumcision
stats may have been inflated. Previous studies have shown
that male circumcision is protective against HPV trans-
mission from male to female partners [23,24]. However, a
recent meta-analysis showed no association between male
circumcision and HPV incidence among several pooled
studies [25].
Limitations in our study included the fact that we were
only able to use baseline questionnaire data and therefore
were not able to evaluate associations between time-
dependent variables and risk of incident HR-HPV infec-
tion. Specifically, we did not have any follow-up information
on a woman’s sexual activity. Therefore, we do not know
if women who reported being a virgin at enrollment, later
became sexually active during the course of the study.
This may bias our estimates of incidence, because we can-
not determine whether these women are truly at risk.
However, HPV is also transmissible through modes other
than nonpenetrative sexual contact, and HPV has been
detected among virgins in other studies [26,27]. The ques-
tionnaire was administered as an in-person interview
during which participants may have been reluctant to
disclose personal information regarding their sexual his-
tory resulting in potential response bias. For example,
our assessment of condom use included broad categories
such as "always" or "never" and was most likely an over-
estimation of condom use among women of reproductive
age in Costa Rica [28]. Our estimation of male circumcision
status was based on the woman's recall and a large pro-
portion of women did not respond to this question,
therefore this variable was highly subject to bias and
misclassification, and probably reflects an overestimation
of circumcision among Costa Rican men [29]. Our study
had several strengths including the large number of
women in our cohort and the narrow age range which
allowed us to observe the early natural history of incident
HPV infections among sexually active young women. The
availability of HPV typing data allowed us to measure the
cumulative risk for type-specific HR-HPV infections.
Conclusions
Our study provides good estimates of HR-HPV, LR-HPV,
and type specific HR-HPV infections among a large co-
hort of sexually active young women. We have confirmed
the sexually transmissible nature of HR-HPV infections
and demonstrated a lack of association between condom
use and female-reported, male partner circumcision sta-
tus and HR-and LR-HPV acquisition. Other risks for
HR-HPV infection included high socioeconomic status
and smoking history, while lifetime use of birth control
pills was protective for incident HR-HPV. Our findings
demonstrate that HR-HPV is extremely common and
underscore the importance of vaccinating young women
before they become sexually active.
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